September 10, 2025European Respiratory ReviewOpen Access

Initiation of antifibrotic treatment in fibrosing interstitial lung disease: is the clock ticking till proven progression?

View Full Paper

Ask AI

Bookmark

Initiating antifibrotic treatment early may enhance outcomes in individuals with progressive pulmonary fibrosis, despite established guidelines.
The review emphasizes the importance of recognizing varied progression criteria among different interstitial lung diseases to improve management decisions.
Challenges in clinical practice demand a more personalized approach to treatment initiation for individuals displaying progressive behavior in interstitial lung disease.
Leveraging technology, particularly artificial intelligence, could improve future management strategies for antifibrotic treatments in interstitial lung disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This review discusses antifibrotic treatment initiation amid challenges in identifying progression of interstitial lung diseases, suggesting flexibility in clinical decisions.

Cite This Study

Gogali et al. (2025) studied this question.

synapsesocial.com/papers/68c241acb210217d647a07c8 https://doi.org/10.1183/16000617.0023-2025

View Full Paper

Ask AI

Bookmark

Implication

This review discusses antifibrotic treatment initiation amid challenges in identifying progression of interstitial lung diseases, suggesting flexibility in clinical decisions.

Initiation of antifibrotic treatment in fibrosing interstitial lung disease: is the clock ticking till proven progression?

Key Points

Discussion

Implication

Cite This Study

Initiation of antifibrotic treatment in fibrosing interstitial lung disease: is the clock ticking till proven progression?

Key Points

Discussion

Implication

Cite This Study